Bharat Parenterals PE ratio history and valuation
NSE: BPLPHARMABSE: 541096Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,802.20.
27 Oct: open ₹1,796.70, high ₹1,920.00, low ₹1,788.40
- Next results date: the board meets on 29 Oct 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,300 Cr1,597th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Owners' profit not stated
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.04
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.05%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −5.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,97266.6% delivered
Bharat Parenterals' price to book, price to sales, EV to EBITDA and dividend yield on 27 Oct 2026, each against its own history of up to 10 years. Its P/E is not shown: the figures it needs for the twelve months to Jun 2026 are not complete or not comparable. The ratios use standalone accounts to Mar 2020 and consolidated from Mar 2021.
Bharat Parenterals PE ratio and valuation against its own history
- Price to earningsA quarter's profit for shareholders does not agree with its own earnings per share
- Price to book4.04today
1 year
Median 2.57Today is at or above 98% of the 247 days
3 years
Median 2.86Today is at or above 78% of the 581 days
5 years
Median 2.09Today is at or above 88% of the 1,072 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.4.02today
1 year
Median 2.42Today is at or above 98% of the 247 days
3 years
Median 2.65Today is at or above 95% of the 727 days
5 years
Median 2.11Today is at or above 97% of the 1,218 days
10 years, since Nov 2018
Median 1.07Today is at or above 98% of the 1,872 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.135.68today
1 year
Median 53.23Today is at or above 98% of the 247 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.05%today
1 year
Median 0.08%Today is at or above 3% of the 247 days
3 years
Median 0.08%Today is at or above 13% of the 743 days
5 years
Median 0.06%Today is at or above 46% of the 1,234 days
10 years, since Apr 2018
Median 0.00%Today is at or above 67% of the 2,031 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A quarter's profit for shareholders does not agree with its own earnings per share
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹322 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹323 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹146 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹12 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹11 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.68,91,963at 30 Sep 2026
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Bharat Parenterals financials ›
Bharat Parenterals valuation at each year end
On the last trading day of each March, the month the company's year ends.Bharat Parenterals dividend history
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 126 | 81 | 192 | 196 | 194 | 648 | 681 | 620 |
| Price to earnings | 9.2 | Earlier quarters restated in the year | 7.5 | 10.3 | Earlier quarters restated in the year | Owners' profit not stated | Owners' profit not stated | Owners' profit not stated |
| Price to book | 1.5 | 0.8 | 1.4 | 1.2 | 1.1 | 3.3 | Shares changed | 1.9 |
| Price to sales | 0.6 | 0.4 | 0.9 | 1.0 | 0.9 | 2.7 | 2.2 | 1.8 |
| EV to EBITDA | 4.5 | 2.9 | 6.4 | 7.8 | 12.8 | Operating profit not stated | Shares changed | 39.6 |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.07% | 0.10% | 0.11% |
| Earnings yield | 10.8% | Earlier quarters restated in the year | 13.3% | 9.7% | Earlier quarters restated in the year | Owners' profit not stated | Owners' profit not stated | Owners' profit not stated |
Bharat Parenterals market cap, since Apr 2018
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Book value and enterprise value
From the close on 27 Oct 2026.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹1,435 Cr
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹467.55
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- ₹1.00
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹427 Cr
Against Pharmaceuticals
216 listed companies in Pharmaceuticals, each priced on its last trading day; Bharat Parenterals is 87th among them by market cap. Each median leaves out Bharat Parenterals itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.4Across 159 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.8Across 146 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.50%Across 88 other companies
| Company | |||||
|---|---|---|---|---|---|
 NGL Fine-ChemNGLFINE | 1,626 | 28.43 | 4.94 | 20.5 | 0.07% |
 Jagsonpal PharmaceuticalsJAGSNPHARM | 1,474 | 32.41 | 5.34 | 22.4 | 1.79% |
 Amrutanjan Health CareAMRUTANJAN | 1,415 | 26.22 | 3.82 | 18.8 | 1.00% |
 Fermenta BiotechFERMENTA | 1,317 | – | 3.24 | 15.4 | 0.84% |
| Bharat ParenteralsBPLPHARMA | 1,300 | – | 4.04 | 135.7 | 0.05% |
 Anlon HealthcareAHCL | 1,297 | 44.65 | 5.64 | 28.2 | 0.00% |
 KopranKOPRAN | 1,205 | 48.22 | 2.27 | 22.1 | 1.20% |
 Lincoln PharmaceuticalsLINCOLN | 1,102 | 11.42 | 1.45 | 10.6 | 0.33% |
 Bafna PharmaceuticalsBAFNAPH | 1,047 | 134.52 | 10.89 | 92.1 | 0.00% |